Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551042 | 0.96 | PDE8B (0.42) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL4406008 | 0.96 | PDE8B (0.42) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL29550324 | 0.96 | PDE8B (0.42) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL4840050 | 0.83 | PARP1 (0.37) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4843363 | 0.83 | PARP1 (0.37) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12836925 | 0.82 | HSD17B10 (0.42) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL1516365 | 0.82 | HSD17B10 (0.42) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL4843374 | 0.81 | PARP1 (0.36) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5849346 | 0.80 | HSD17B10 (0.45) | MEN1KMT2AALDH1A1HSD17B10PDE8B | |
| SCHEMBL5848840 | 0.80 | HSD17B10 (0.45) | MEN1KMT2AALDH1A1HSD17B10PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | MEN1 1130/4885KMT2A 3062/4885ALDH1A1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.